FDA approves first direct-acting antivirals for adolescents with hepatitis C

7th grader wins awards for ‘remarkable’ science fair project on cancer research
April 27, 2017
Breakthrough in multiple sclerosis research as scientists discover possible cause of the disease 
April 27, 2017
Show all

FDA approves first direct-acting antivirals for adolescents with hepatitis C

Two medications are approved to treat hepatitis C infection in teens.

The US Food and Drug Administration (FDA), which is responsible for evaluating the safety and efficacy of medicines in the United States, has approved Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) for the treatment of hepatitis C in adolescents aged 12–17 years. The drugs are the first direct-acting antiviral treatments to be approved for treating this age group.

“These approvals will help change the landscape for hepatitis C treatment by addressing an unmet need in children and adolescents,” says Edward Cox, director of the Office of Antimicrobial Products, FDA Center for Drug Evaluation and Research.

Read full article: FDA approves first direct-acting antivirals for adolescents with hepatitis C | News in brief | Pharmaceutical Journal

Read Full Article: FDA approves first direct-acting antivirals for adolescents with hepatitis C | News in brief | Pharmaceutical Journal

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.